RBR-4pfygr
Not yet recruiting
Phase 1
Clinical study to evaluate the safety and tolerability of intravenous infusion of plasma from human umbilical cord and placental blood (Plasmacord®) in patients with Severe Acute Respiratory Syndrome resulting from Sars-Cov-2 infection
CRYOPRAXIS - CRIOBIOLOGIA LTDA0 sitesAugust 13, 2020
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- CRYOPRAXIS - CRIOBIOLOGIA LTDA
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age over 18 years; both sexes; positive test for COVID\-19; indication for transfer to the intensive care unit (ICU) by the responsible medical team; according to institutional criteria and protocols; absence of therapeutic alternative
Exclusion Criteria
- •Pregnant women; under 18 years old; no indication of transfer to the intensive care unit (ICU) by the responsible medical team; according to institutional criteria and protocols; existence of therapeutic alternative
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to evaluate the safety of human immune globulin in patients withprimary immunodeficiency diseases.EUCTR2011-005015-82-Outside-EU/EEAOctapharma AG20
Completed
Phase 3
Clinical study to evaluate the safety and tolerability of immunoglobulin intravenous (human) 10% (NewGam) administered at high infusion rates to patients with primary immunodeficiency diseasesISRCTN11002924Octapharma AG (Switzerland)35
Not yet recruiting
Phase 1
A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adultsovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003169anjing University
Recruiting
Not Applicable
safety and effectiveness of Soreze gel in pressure ulcerHealth Condition 1: L899- Pressure ulcer of unspecified siteCTRI/2021/06/034297Amaterasu Lifesciences
Unknown
Phase 2
A study to evaluate ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Japanese adults with chronic Hepatitis C Virus infectioJPRN-jRCT2080221883AbbVie GK96